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Understanding patient activation and
adherence to nebuliser treatment in adults
with cystic fibrosis: responses to the UK
version of PAM-13 and a think aloud study
Jie Gao1* , Madelynne Arden1, Zhe Hui Hoo2,3 and Martin Wildman2,3
Abstract
Background: Patient activation refers to patients’ knowledge, skills, and confidence in self-managing health
conditions. In large cross-sectional studies, individuals with higher patient activation are observed to have better
health outcomes with the assumption that they are more engaged in health self-management. However, the
association between patient activation and objectively measured self-care indicators in individuals can be
inconsistent. This research investigated the role of patient activation as measured by the UK Patient Activation
Measure (PAM-13) in adults with Cystic Fibrosis (CF). The aims were twofold: to explore how adults with CF
interpret and respond to the PAM-13; and to investigate the association between PAM-13 and objectively
measured nebuliser adherence in UK adults with CF.
Methods: This article describes two studies which examined the PAM-13 from different perspectives. Study 1 comprised
‘think aloud’ interviews with 15 adults with CF. The data were analysed using an a priori coding framework. Study 2
examined the association between PAM-13 and objectively measured nebuliser adherence in 57 adults with CF.
Results: Study 1 showed that adults with CF encountered several difficulties while completing the PAM-13. The
difficulties were related to understanding how to interpret aspects of CF in order to respond (i.e., control over the
condition, ability to exercise) and item wording. Some adults with CF responded to the PAM-13 in an optimistic way in
relation to what they thought they should do rather than what they actually do. These findings were echoed by the
results of Study 2, which showed that PAM-13 scores were not significantly correlated with objective medication
adherence in a different sample. This article synthesises the results of both studies, providing insights into influences and
associations of patient activation as measured by the UK PAM-13 in adults with CF.
Conclusions: There were some significant difficulties created by the wording of the UK PAM-13 for adults with CF. This
may partly explain the finding that PAM-13 scores were not related to objectively measured nebuliser adherence in this
study. The UK PAM-13 would benefit from further research to verify its validity and reliability in different patient
populations against objective measures of behaviour rather than simply self-report.
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Background
Patient activation is a concept that is used to describe a
patient’s knowledge, skills, and confidence in managing
his or her health conditions [1]. Conceptually, patient
activation describes the characteristics of patients who
are more likely to participate as active members of their
care team [2], and engage in the behaviours that main-
tain their health such as adherence to medication [1].
The Patient Activation Measure (PAM) was developed
using the findings from an expert consensus panel and
patient focus groups to identify and define the question-
naire domains and subsequent testing and refinement
using psychometric analysis [1]. Patient activation draws
on concepts such as health locus of control [3], self-
efficacy in managing health behaviours [4] and readiness
to change health behaviours [5], but is not condition or
behaviour specific. The original Patient Activation Meas-
ure (PAM) has 22 items and a 13-item version has also
been developed (PAM-13) [6]. Both utilise a four-point
Likert scale of agreement-disagreement to respond to
each item. PAM is scored on a scale from 0 to 100 from
which four levels of activation have been identified:
Level 1 (0.0–47.0) low activation suggesting that the per-
son does not yet understand their role in healthcare;
Level 2 (47.1–55.1) indicating that the person does not
yet have the knowledge and confidence to take action;
Level 3 (55.2–72.4) indicating that the person is begin-
ning to engage in positive health behaviours; Level 4
(72.5–100) indicating that the person is proactive and
engaged in recommended health behaviours [7].
There is some self-report evidence that individuals with
higher patient activation are more engaged in self-managing
their long-term conditions, thereby having better health out-
comes and care experiences. For example, Mosen et al. [8]
described the results from a cross-sectional survey of over
4000 people with a range of chronic health conditions. They
reported positive relationships between PAM-22 scores and
self-reported measures, including self-management behav-
iours, use of self-management services, and medication ad-
herence as well as patient satisfaction, quality of life, and
physical and mental functional status. Barker et al. [9] ana-
lysed a database of English NHS and found that high patient
activation was associated with lower healthcare utilisation
and less wasteful use across primary and secondary care.
Kinney et al. [10] conducted a systematic review of pub-
lished literature on the association between the PAM and
hospitalization, emergency room use, and medication adher-
ence among chronically ill patient populations. The review
indicated that lower PAM scores were associated with
higher rates of hospitalisation and use of emergency room
services but that the relationship with adherence to medica-
tion was inconclusive.
The PAM has been widely used in the US as a tool to
measure and target support for patient engagement and
self-management, particularly with regard to long-term
conditions. It has also been translated and validated for
use in several languages and countries [11].
The PAM was introduced into UK in 2005. Ellins and
Coulter [12] validated the 22-item PAM in a National
Telephone Survey study in the UK. They anglicised
some key terms and phrases to better suit the UK popu-
lation. Subsequently, the validated PAM (mostly 13-item
version) has been used as an outcome measure to evalu-
ate intervention programmes in the UK [13–16]. Use of
the PAM is becoming much more frequent in the UK,
and NHS England has agreed a five-year licence to use
the PAM-13 with up to 1.8 million people across the
NHS from 2016 as part of its ‘Self-Care programme’ [17]
which seeks to support people living with long-term
health conditions to better manage their own health.
Five Clinical Commissioning Groups (CCGS) and one
disease registry are currently using PAM across a range
of projects [17]. However, some concerns have been
raised about the appropriateness of the UK-version of
PAM in these contexts [17].
Kidd et al. [18] examined the content and wording of
the PAM-13 and its ease of use in UK stroke survivors.
Some patients reported that they found it difficult to re-
spond to certain items. For example, the item “I under-
stand my health problems and what causes them”
actually indicates at least two distinct health issues (A.
understanding the health problem and B. understanding
what causes the health problem), which the patients re-
ported that they might have different responses. Kidd et
al. [18] also found that patients’ PAM-13 scores did not
necessarily match the narratives which patients provided
about their activation levels.
Armstrong et al. [19] conducted an independent evalu-
ation of the feasibility of using the PAM-13 in the NHS
in England and identified some potential problems. For
example, some health coaches reported that their pa-
tients struggled with the meaning of some items of the
PAM-13 and found some items irrelevant to their health
conditions. The health coaches suggested that patients
may not engage with the PAM-13 properly. Moreover,
Armstrong et al. [19] found that the PAM-13 seemed to
be problematic for patients with multiple co-morbidities,
as their responses tended to vary depending on which
health condition they were thinking about when com-
pleting the measure. The generalised wording of the
PAM-13 makes it difficult for patients with multiple co-
morbidities to respond with certainty as they may want
to respond differently depending on which one of the co-
morbid conditions they choose to focus on. Nonetheless,
Blakemore et al. [20] used the PAM-13 in older people
with multiple co-morbidities in the UK and found that the
PAM scores were associated with the number of self-
reported co-morbidities and the perceived impact of those
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comorbidities. The use of PAM-13 in UK patients with
multiple co-morbidities is therefore unclear.
Cystic fibrosis (CF) is a life-limiting genetic condition
with multiple effects on the body. Acute and chronic
lung infections are common in adults with CF and ad-
herence to medication is crucial to reduce exacerbations
and preserve lung function. Nebuliser treatments are
prescribed as preventative treatment, however as with
other long-term conditions adherence is low [21] with
objective data indicating that median adherence is only
36% [22]. Many people with CF also have co-morbidities
including diabetes [23]. Patient activation and resultant
engagement with self-management is therefore a poten-
tially important concept in CF care.
In order to investigate the role of patient activation as
measured by the UK PAM-13 in adults with CF, two
studies with different foci were conducted separately in
the UK. The first study aimed to explore how adults
with CF interpret and respond to the UK version PAM-
13. The second study analysed data from a pilot rando-
mised controlled trial to examine the association be-
tween the PAM-13 and objective measures of nebuliser
adherence in adults with CF at baseline and five-month
follow-up. This article synthesises the findings of both
studies in order to provide multifaceted perspectives on
the results obtained when patient activation is measured
by the UK PAM-13 in adults with CF.
Methods
Design
This article combines two studies of patient activation
which were carried out separately in the UK. Each study
demonstrates a different aspect of the application of the
UK PAM-13 in adults with CF.
Study 1 utilised the think-aloud technique to investi-
gate how adults with CF understand and respond to the
PAM-13. Think-aloud is a cognitive interview technique
that enables participants to verbalise thoughts that
would normally be silent [24]. It is an established tech-
nique to investigate an individual’s response process
when completing a questionnaire [25].
Study 2 investigated the association between the
PAM-13 and objectively measured adherence to nebu-
liser medication in adults with CF measured at two time
points as part of a pilot randomised controlled trial of
an intervention (CFHealthHub) [26].
Participants
For study 1, participants were recruited from a Cystic Fi-
brosis centre in the North of England. The Inclusion cri-
teria were that they were English-speaking patients with
CF, aged 16 years and above who were using an Etrack®
nebuliser (Pari) which collects objective data about the
date and time that treatments are taken. Participants
were excluded if they were pregnant, post-transplant, or
on the active transplant list or in the palliative phase of
disease.
One hundred six patients met the above criteria. We
contacted 39 participants who represented a range of
participant characteristics based on their objective ad-
herence level (high/low1), lung function (good/poor2)
and with/without a co-morbidity of diabetes. Fifteen pa-
tients (6 females and 9 males) consented to participate
(see Fig. 1 and Table 1).
For study 2, participants were recruited from two
other Cystic Fibrosis centres in the UK (one in the mid-
lands and one in the south of England) to take part in a
pilot study of an intervention to increase adherence to
nebulised medication [26]. Eligible participants were
aged 16 years and over, taking or willing to take inhaled
medication via a nebuliser with data recording and
transfer capability. We excluded those who were: post-
lung transplant; on the active transplant list; receiving
palliative care; lacking capacity for informed consent; or,
using other devices to take their inhaled treatment
which did not provide objective adherence data. Four
hundred thirty patients were screened and 135 (31.4%)
were eligible. Ninety-five were able to be contacted and
64 (Mean age = 29.7, 56% male) consented and provided
data at baseline (see Table 2 for full baseline characteris-
tics). Two participants died, one withdrew consent, two
were lost to follow-up, and two withdrew from adher-
ence data collection over the course of the study so that
57 participants provided data at follow-up.
Measures
The Patient Activation Measure (UK PAM-13)
Patient activation was measured using the PAM-13® (In-
signia, UK version). This consists of 13 items, with a 4-
point Likert scale for each item from agree to disagree.
Scoring of the questionnaire was completed using the
scoring algorithm provided by Insignia.
Medication adherence
Objective adherence was measured using an Etrack® nebu-
liser (Pari). The data were used to calculate the percentage
of treatments taken relative to the number prescribed. For
Study 1, the most recent 12-month of data in the period
from 01 Jan 2016 to 31 Mar 2017 were used. For Study 2,
the data over 2 two-week3 periods at baseline and five-
month follow-up, respectively, were used.
Procedure
In Study 1, eligible participants were invited to inter-
view. Interviews took place either at the hospital or at
the patient’s home. Participants were provided with in-
formation about the study and provided written consent
to take part. All interviews were audio-recorded and
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transcribed and any identifiable information was re-
moved. Names were replaced by a code which reflected
level of adherence, lung function and whether or not
they had diabetes (see Table 1). Each interview took ap-
proximately half an hour.
During the think aloud procedure, participants were
asked to speak everything that they were thinking about
while completing the questionnaire with minimum inter-
ference from the researcher. Participants were not re-
quired to reflect on their thoughts during thinking
aloud. Rather they were asked to report their thoughts
concurrently. As a result, the authentic thoughts of the
participants were recorded for analysis.
Instructions on how to ‘think-aloud’ were provided to
the participant. They then watched a video clip of a
think-aloud interview in response to a different ques-
tionnaire. Next, a warm-up questionnaire was given to
the participant to practice ‘thinking aloud’. During the
process, the researcher checked whether the participant
understood and could perform ‘thinking aloud’ properly
and answered any questions as necessary. The partici-
pant then completed the PAM-13 while ‘thinking-aloud’.
The researcher did not interrupt unless the participant
paused for more than 10 sec when the researcher asked
the participant to “keep talking please”. After the
participant completed the PAM-13, the completed ques-
tionnaire was collected and a few follow-up questions
were asked, such as “what do you think about the ques-
tionnaire? Which statements do you find most difficult
to respond to?”. At the end of the interview, participants
were debriefed and provided with contact information of
the researchers.
In Study 2, measurements were taken as part of the pro-
cedures in a pilot randomised controlled trial of an inter-
vention (CFHealthHub) to increase nebuliser adherence in
adults with CF, which is described elsewhere [26].
Participants who met the inclusion criteria consented
to take part and completed a battery of questionnaires
including the PAM-13 at baseline. They were then pro-
vided with an E-track nebuliser and Qualcomm hub
which they plugged in at their home and this sent data
about the date and time of nebulised treatments to the
CFHealthHub web platform. They then completed the
questionnaire battery including the PAM-13 at five-
month follow up.
Mean objective adherence data (number of treatments
taken/number of treatments prescribed) was calculated at
baseline (14 days post-consent with the PAM measured at
consent) and follow-up (14 days preceding the completion of
follow-up questionnaires).
Fig. 1 Procedure of participant recruitment of study 1
Table 1 Participant characteristics of each category for study 1
Category code Patient characteristics NO. of participants
GL-HA Good lung function, High adherence, Without diabetes 2
GL-HA-D Good lung function, High adherence, With diabetes 1
GL-LA Good lung function, Low adherence, Without diabetes 2
GL-LA-D Good lung function, Low adherence, With diabetes 2
PL-HA Poor lung function, High adherence, Without diabetes 2
PL-HA-D Poor lung function, High adherence, With diabetes 2
PL-LA Poor lung function, Low adherence, Without diabetes 2
PL-LA-D Poor lung function, Low adherence, With diabetes 2
Total 15
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Analysis
In Study 1, the audio-recording of the interviews were
transcribed verbatim. The transcripts were analysed
using an a priori coding framework which classifies the
data into codes based on suitable question, problematic
content and misinterpretation (see Table 3 for details).
This coding framework has been used in previous cogni-
tive interview studies showing it is a sound framework
for evaluating questionnaires [31, 32]. The data was
firstly coded in accordance with the framework. Subse-
quently, the data under each code were analysed to gen-
erate themes representing the rationale for the initial
coding [31]. The codes and the corresponding themes
were discussed between two researchers (JG and MA)
and a consensus was reached.
In study 1 and 2, PAM-13 scores and levels (1–4) were
calculated for participants at baseline and follow-up
using the scoring algorithm provided by Insignia. Per-
centage objective nebuliser adherence was calculated at
baseline and follow-up and then categorised as being
very low (< 25%), low (25.1–50%), moderate (50.1–75%)
or high (> 75%) according to Hoo et al. [27].
Results
Study 1: A think-aloud study of completion of PAM-13 by
adults with CF
In study 1, the result showed that the majority of partici-
pants (12 out of 15) were at PAM Level 3 and above.
Table 4 illustrates the PAM levels of activation of the
participants. As can be seen, five of the eight partici-
pants who had low objective adherence were scored at
Level 3 or Level 4 in the PAM-13. Figure 2 illustrate the
percentage of participants in each adherence category
with a given PAM level.
The results of content analysis are presented in ac-
cordance with the a priori coding framework. Each code
is elaborated with corresponding themes and examples
of quotes. Table 5 illustrates the results of coding of the
data relating to each item.
Code 1: Suitable item
No problems were identified for items 1, 2, 4 and 6. The
data showed that participants had no difficulties in
responding to these items, for example, “ … and number
two: taking an active role in my own health care is the
most important thing that affects my health. Yes, again I
agree and obviously my parents help a bit and sort of the
hospital staff as well, so I will say I agree” (GL-HA-D01).
Some participants indicated that completing the PAM-
13 helped them to reflect on their health self-
management, for example, “It would help some of the pa-
tients; I dare say it has helped me a bit, doing it now, be-
cause it is some things you don’t think about. And you sit
back and think about it while you are filling the form
in.” (PL-HA-D02).
Code 2: Problematic content
This code represents the data that participants questioned
about the item content or wording or scale categories.
There are five themes under this code, namely, lack of
control over preventing problems, uncertainty resulting
from co-morbidities, asking two things in one question,
ambiguous wording and scale problem. The items in-
volved in this code are Item 3, 8, 9, 10, 11, 12, and 13.
Theme 1: Lack of control over preventing problems
The data showed that participants found Items 3 and 11
were not suitable for people with CF. Participants re-
ported that it is very difficult to prevent problems in CF
as some conditions are unpredictable. Despite taking ac-
tion to prevent problems, they may still find their condi-
tions deteriorated. For example,
“[Item 3: I am confident I can help prevent or reduce
problems associated with my health] … I can’t prevent,
but I can reduce sometimes … a difficult one, because
with CF you can’t really have direct, you can’t have
direct impact on what CF does to you. What it does it
does, what you do with CF, what I do with my CF is
kind of react to what it does... I want to say not
applicable for me because I am not sure if I can
reduce problems because CF is CF, I can do the physio
which helps alleviate the symptoms a little bit, but the
underlying condition, I don’t think I can change
anything about it.” (PL-HA01)
Table 2 Baseline characteristics of study 2 participants
Baseline
Age
Mean (SD) 29.7(11.5)
Median (IQR) 27(21, 36)
Sex
Male 36 (56%)
Female 28 (44%)
FEV 1% Predicted
Mean (SD) 57.3 (21.3)
Median (IQR) 49.6 (41.9, 76.7)
Table 3 The a priori coding framework
Coding framework
Code 1 Suitable item No problems emerged
Code 2 Problematic content Participants questioned about the item
content or wording or scale categories.
Code 3 Misinterpretation Participants misunderstood the items
or their verbal responses did not justify
their choices.
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“[Item 11: I know how to prevent problems with my
health] … certain problems [I know how to prevent],
and then there’s others I don’t know how to stop from
happening. I think I’d have to put N/A for that one.”
(PL-LA-D01)
Theme 2: Uncertainty resulting from co-morbidities
Due to multiple co-morbidities of CF, participants indi-
cated that their answers could be different in reference
to different conditions and therefore they were unsure
about which response to choose. The generalised con-
tent of items generates uncertainty for people with CF
with multiple co-morbidities. For example,
“[Item 8: I understand my health problems and what
causes them.] This is only relating to CF, because I
have got other health problems that impact on my CF,
so I am not sure what the answer to that one, because
I don’t really understand all my health issues and why
they may affect my CF, because I have Meniere’s
Disease as well and that strongly affects the
medication I can take with CF, so that’s a hard one
and the options I have got fall somewhere in between.”
(GL-LA-D02)
“[Item 12: I am confident I can figure out solutions
when new problems arise with my health.] I don’t
know if that’s an agree or disagree to be honest. I think
it depends what it is, what the problem is. For some
problems yes I’m confident but others not so I don’t
know that one … So if it’s something that you know
about, if it’s a definite thing, for example, if it’s a
normal CF chest problem then the solutions are you
get some IV’s or some drugs or whatever it is that you
know are available, that’s the solution or one of the
solutions whereas I have nose problems as well, for
example and as far as I know that’s it now, there’s
nothing that can be done about it so I guess you can
figure some solutions out but not everything’s got an
answer to it.” (PL-HA02)
Theme 3: Asking two things in one question Partici-
pants suggested that Item 10 and 13 asked two different
things in one question (i.e., eating right and exercising).
They may agree with one thing but disagree with the
other, which made it difficult to respond to the items.
Participants with poor lung function indicated that it
was impossible for them to do any exercise and there-
fore the exercising component of these two items was
problematic for them. For example, participant PL-LA02
said that “I am a bugger for exercising so I would agree
only on the basis of one of those options, but actually I
think there’s probably more than one question in there
and that probably needs to be split out I think”.
Theme 4: Ambiguous wording Some participants
found the wording of Item 9 and 12 vague and ambigu-
ous. They indicated that they were unsure about what
exactly the items were asking and therefore found it dif-
ficult to respond to. For example,
“[Item 9: I know what treatments are available for
my health problems.] I wasn’t quite sure what it
really, you know so things like, as I said knowing
about what treatments are available as well, is it
asking about all possible treatments or is it just
asking about the routinely available ones in your
own hospital. I think it means the latter rather
Table 4 PAM Levels of activation of the participants in study 1
PAM level Participant ID NO. of participants by objective adherence category
Low High
Level 1 GL-LA-D02 1 0
Level 2 GL-LA-D01, PL-LA02 2 0
Level 3 GL-LA02, PL-LA01, PL-LA-D01, PL-LA-D02,
GL-HA02, GL-HA-D01, PL-HA01, PL-HA02, PL-HA-D01,
4 5
Level 4 PL-HA-D02, GL-HA01, GL-LA01 1 2
Fig. 2 Percentage of PAM level by Low or High objective adherence
in study 1
Gao et al. BMC Health Services Research          (2019) 19:420 Page 6 of 12
than everything that might be possible in the entire
world.” (GL-LA01)
“[Item 12: I am confident that I can figure out
solutions when new problems arise with my health.]
What does that mean? On my own? That’s not a very
well worded question. I don’t think, because I don’t
know if that means I have to do it on my own or
involve professionals, so I guess agree, but perhaps,
well I am not clear.” (GL-HA01)
Participants also pointed out that the wording (i.e., main-
tain lifestyle changes) in Item 10 and 13 seemed problem-
atic. Participant PL-HA-D01 said “That is a slightly
confusing wording, because you can’t maintain a change. I
suppose you can, but it is like, you can’t keep changing”.
Theme 5: Scale problem Some participants found the
4-point scale problematic (i.e., too few categories) and
sometimes difficult to respond to.
“I think it’s a bit ambiguous at best because you’ve got,
you’ve basically got four options and I think most
questions have a lot more than four options, so I think
sometimes it’s hard to circle one of the four because in
life things don’t neatly fall into options like that. So, I
don’t find these that useful, in practice for myself,
because what you tend to do in life is far more
complexed than a set of options. That is like a set of
one to four options. And my life doesn’t fall into
categories.” (GL-LA-D02)
Code 3: Misinterpretation
This code represents the data that participants either
misunderstood the items or answered optimistically. The
items involved in this code are Item 3, 5, 7, 9, 11 and 12.
Theme 6: Misunderstanding This theme represents the
situation when participants misunderstood the items and
therefore answered a different question. For example,
“[Item 9: I know what treatments are available for my
health problems.] I am going to say disagree because
things with the UK and US differ so much that
sometimes you hear of a lot of treatments that just
aren’t available here and vice versa.” (GL-LA02)
This participant was considering availability of treat-
ments in a very broad sense, including those that were
not approved for use within the UK.
Theme 7: Answering optimistically This theme repre-
sents the data that participants answered optimistically
and their verbalised responses did not justify their an-
swers. In particular, some participants pointed out that
sometimes they knew what they should do but it does not
necessarily mean that they would take action. As a result,
they would agree with the items in theory but admitted
that it may not be the case in practice. For example,
“[Item 5: I am confident that I can tell whether I need to
go to the doctor or whether I can take care of my health
problem myself.] Agree strongly although just because I
feel like I should go to the doctor, it doesn’t mean that I
will, but I think especially when you’ve had something
from birth you definitely get to know your own chest and
symptoms. (Agree strongly)” (GL-LA02)
“[Item 3: I know how to prevent problems with my
health.] Yes I would strongly agree, yes. I know how to
prevent it, doesn’t mean I always do it, so yes, agree
strongly (Agree strongly)” (PL-HA02)
“[Item 7: I am confident that I can follow through on
medical treatments I may need to do at home.] I am
going to put agree because whilst I can, the can do it
and the actual doing it, it is, maybe the can is a bit
ambitious because it’s, is it knowing what you have to
do? I can do it, I know what I have to do with my
nebulisers … or is it the, have the time to and that sort
of thing … it could be seen as two different questions.
Yes, I know what I am doing, I know what I should be
doing, it is the fitting it in. so we’ve gone for
agree.(Agree)” (PL-HA-D01)
“[Item 12: I am confident I can figure out solutions
when new problems arise with my health.] Well I’d
certainly like to think I could do that. But that’s
alright in theory, it is just in practice really.(Agree)”
(GL-HA-D01)
“[Item11: I know how to prevent problems with my
health.] I suppose that’s similar to question 3. I
probably interpret that in the same way as question 3
Table 5 Results of coding of the data relating to each item
1 2 3 4 5 6 7 8 9 10 11 12 13
Code 1 Suitable item ✓ ✓ ✓ ✓
Code 2 Problematic content ✓ ✓ ✓ ✓ ✓ ✓ ✓
Code 3 Misinterpretation ✓ ✓ ✓ ✓ ✓ ✓
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really, I agree. Again it is I know what I should be
doing, whether that actually works is a different
matter, or whether you can fit in what you should be
doing.(Agree)” (PL-HA-D01)
Study 2: The association between PAM-13 and objectively
measured adherence to nebuliser treatment
In study 2, the frequency of PAM level by objective ad-
herence category at baseline and five-month follow up is
illustrated in Table 6. To further demonstrate the PAM
level composition of each objective adherence category,
Figs. 3 and 4 show the percentage of participants in each
objective adherence category with a given PAM level.
While we would expect to see low levels of PAM associ-
ated with low levels of objective adherence, this does not ap-
pear to be the case at either time-point. This was confirmed
in an analysis using Cohen’s kappa which showed a lack of
agreement between PAM levels and objective adherence cat-
egory at baseline (κ = .03 (95% CI, −.09 to .15), p = .303) and
at five-month follow-up (κ = .03 (95% CI, −.08 to .14),
p = .292).
Using the continuous variables of PAM score and ob-
jective adherence percentage Pearson’s correlations also
showed no relationship between PAM and adherence at
baseline (r = 0.14, p = 0.28, n = 64) and follow-up (r =
0.06, p = 0.68, n = 57).
Discussion
This research consists of two related studies investigat-
ing the patient activation measure (PAM) in patients
with Cystic Fibrosis (CF), a long-term condition with
important co-morbidities in which self-management is
critical to optimum outcomes.
The findings of the ‘think aloud’ interviews (Study 1)
have raised some concerns about the validity of using
the UK PAM-13 in adults with CF to identify patients
with high or low activation with the assumption that
those who are highly activated are likely to be successful
in managing their disease. These concerns may apply to
other long-term conditions with multiple co-morbidities.
Items within the PAM-13 asking about ‘preventing
problems’ (Item 3 and 11) were identified as not being
appropriate for patients with CF as some aspects of the
condition and its progression are outside of the control
of the individual. This also applies to patients with other
long-term conditions, for example, Armstrong et al. [19]
reported that patients with inoperable cancer and motor
neurone disease found the item of ‘preventing problems’
inappropriate to their situation.
Items that asked about two things (i.e., eating right
and exercising) in one question were also identified as
problematic particularly because some patients with
poor lung function have significant difficulties in exercis-
ing. This problem also pertains to other patients whose
conditions limit physical activity exercise, and similar is-
sues may arise for people with conditions which affect
appetite and eating. According to Hibbard et al. [1], the
PAM-13 was designed to be used in a wide range of
chronic conditions. However, the present findings sug-
gest that patients with certain conditions may find some
items inappropriate or inapplicable to them.
The PAM-13 is designed to be applicable across condi-
tions and therefore does not provide any context or
guidance on which condition it is referring to and this
means that patients with co-morbidities may find it diffi-
cult to respond to the items with certainty. Thus their
answers may differ depending on to which condition
they refer. This may cause confusion and misunder-
standing when a healthcare professional is trying to infer
a patient’s activation by reading the PAM-13 scores. A
similar finding was reported by Armstong et al. [19] that
patients with depression indicated they struggle to an-
swer the PAM-13 as their self-care depends on their de-
pression. Without clearer instruction or additional
guidance from professionals, patients with multiple co-
morbidities may not be able to provide informative and
credible answers to the PAM-13.
Hibbard and Gilburt [11] indicate that “patient activa-
tion captures not only the patient’s beliefs about their
ability to self-manage but also the likelihood that they
will put these beliefs into action” (p.11), however our
data suggests that this is not the case in this sample and
indicates that one of the reasons for this is that
Table 6 Frequency of PAM level by objective adherence category at baseline and follow-up (5 months)
PAM level Baseline objective adherence Total 5 month follow up objective adherence Total
v.low low moderate high v.low low moderate high
n n n n n n n n n n
1 3 3 2 0 8 5 2 1 3 11
2 11 4 1 1 17 7 2 0 1 10
3 14 4 4 7 29 9 10 3 9 31
4 6 0 1 3 10 2 1 0 2 5
Total 34 11 8 11 64 23 15 4 15 57
Note: “v.low” means < 25%; “low” means 25.1–50%; “moderate” means 50.1–75%; “high” means > 75%
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participants sometimes responded according to what
they thought they should do rather than what they actu-
ally did. This is consistent with a large body of data
showing that there is a gap between intentions and be-
haviour such that around half (median 53%) of people
who intend to perform a behaviour go on to perform the
action [33]. Participants pointed out that a number of
factors (i.e., social contexts, life situations, conditions,
etc.) may constrain their action even though they ideally
wanted to take the actions. While participants could be
instructed to answer according to what they do rather
than what they think they should do, this instruction is
not currently included on the PAM-13 questionnaire
and the official guidance for administering the PAM-13
emphasises standardised administration.
The ‘think-aloud’ study showed that patients with CF
encountered a number of problems and difficulties when
answering the PAM-13, which raised the question of
whether patients need additional help to fill in the PAM-
13 in order to obtain an informative and credible out-
come. Chew et al. [17] conducted an ethnographic study
of the implementation of the PAM and they suggested
that standardised administration of the PAM was chal-
lenging and may exclude certain patient groups. Our
findings support Chew et al.’s [17] argument. If the
PAM-13 is to be used as a research tool (e.g., evaluate
Fig. 3 Percentage of PAM level by objective adherence category at baseline in study 2
Fig. 4 Percentage of PAM level by objective adherence category at follow-up in study 2
Gao et al. BMC Health Services Research          (2019) 19:420 Page 9 of 12
interventions) or in situations where careful direction or
additional help is not possible, the results of the PAM-
13 need to be interpreted with caution.
The wording of the UK version PAM-13 is different
from the original PAM-13. When Ellins and Coulter [12]
first introduced the PAM-13 to the UK, they anglicised
some wording of items, and this anglicisation included
changes to some of the items that participants found
most challenging to answer. The wording was modified
to make them more suitable for telephone survey, al-
though it is not clear whether these items are appropri-
ate for paper-and-pen test and whether this UK version
has been fully validated. Based on our ‘think-aloud’ data,
it may be that the original US wording of Items 3, 10
and 13 may be more appropriate than the modified UK
version. More empirical evidence is needed to verify the
modified wording of the UK version PAM-13.
The quantitative results (Study 2) are consistent with
the findings of the ‘think aloud’ interviews (Study 1).
The results show no significant correlation between the
PAM-13 scores and objective measures of nebuliser ad-
herence in adults with CF at either the baseline or the
follow-up point. Most of the previous studies that have
demonstrated evidence of the positive relationship be-
tween PAM levels and medication adherence have been
based on self-reported adherence measures, which are
known to be subject to self-report bias [19]. Evidence
of an association between PAM scores and objectively
measured self-care behavioural data is less convincing.
Shah et al. [32] used PAM and clinical parameters (i.e.,
mean levels of A1C, fasting blood glucose, BMI, total
cholesterol, and triglycerides) to evaluate an interven-
tion programme. They reported that changes in clinical
parameters were not correlated with either PAM level
at baseline nor change in PAM level from baseline to 6
months [32]. Likewise, Mayberry et al. [34] found Pa-
tient Activation was unrelated to glycemic control
among adults with Type 2 diabetes. These findings con-
cur with the present study, suggesting that PAM scores
are not necessarily related to objectively measured data
of self-care.
Limitations
Both studies in this research were relatively small-scale
and focused on a specific patient sample, i.e., adults with
CF. Given the specific characteristics of CF, generalisa-
tion of the findings to other chronic conditions should
be with caution. Nonetheless, the findings show that
some items might be problematic for patients with some
long-term conditions or co-morbidities. Future studies
may seek to evaluate the PAM-13 in other patient popu-
lations with long-term conditions and multiple co-
morbidities.
Implications
The PAM-13 is currently being used in a number of set-
tings, for example, as a tailoring tool to inform health
coaching and service delivery; and as an outcome meas-
ure to evaluate care provision [19]. While PAM serves as
a useful tool to predict outcomes associated with self-
care in cross-sectional studies with large sample size, its
application in individual cases should be carried out with
caution. The findings in our study suggest that in some
situations the activation data based on PAM may be un-
reliable and may result in support being inappropriately
targeted. It is therefore vital that health professionals are
aware of these potential discrepancies and where possible
utilise objective measures of self-care such as objective ad-
herence data to verify the PAM level categorisation.
Health professionals should also be aware of the difficul-
ties that some items might pose and provide patients with
support and guidance to answer appropriately.
Conclusions
This research investigated the role of patient activation
in medication adherence of patients with CF. Instead of
relying on self-report medication adherence as most of
previous studies did, this research adopted objectively
measured medication adherence which is more accurate
than self-report data. The results suggested that patient
activation as measured by the UK PAM-13 was not reli-
ably associated with objectively measured adherence to
medication. This may well result from difficulties in
responding to specific items and because some partici-
pants responding according to what they knew they
should do, rather than what they actually did. It seems
likely that patients with similar long-term conditions
and patients with multiple co-morbidities, may also find
it difficult to respond to the PAM-13. Further research is
therefore needed to verify the validity and reliability of
the UK version PAM-13 in different patient populations.
Endnotes
1Nebuliser adherence data were used to indicate high
or low adherence. Nebuliser adherence data were object-
ively captured with chipped devices (E-track®). Adher-
ence was calculated as a percentage between total
amount of medication used against the agreed dose be-
tween clinicians and adults with CF and clustered ac-
cording to a pragmatic algorithm-based clustering
method [27]. The most recent 12-month of data in the
period from 01 Jan 2016 to 31 Mar 2017 for each poten-
tial participant was used for clustering (very low adher-
ence < 25%; low adherence 25.1–50%; moderate
adherence 50.1–75%; high adherence > 75%) [27].
2Participants’ lung function was defined by their FEV1.
The best % predicted FEV1 (calculated with Knudson
equation) [28] from 01 Jan 2016 to 31 Dec 2016 for each
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potential participant was used. % FEV1 ≥ 70% was classi-
fied as high (i.e., good lung function), which is the stand-
ard cut-off used in CF epidemiological studies [29].
Similar cut-off also applies well for the UK data [30].
Conversely, % FEV1 < 70% was classified as low (i.e.,
poor lung function).
3The first two-week period was at baseline (i.e., 14 days
post-consent); while the second two-week period was at
the five-month follow up (i.e., 14 days preceding the
completion of follow-up questionnaires).
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